The HER2+ subtype, derived from the amplification of the HER2 oncogene, comprises 15–20% of all BCs; the remaining 15–20% represents triple‐negative (TN) BC, which lacks ER, PR, and HER2. The gene discussed is ERBB2; the disease is breast cancer.